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Abstract
Genistein is known as the major component of isoflavone, which is present in high-soy diets. Genistein has received 
much attention because of its chemopreventive and therapeutic effects on various types of cancers. Numerous studies 
have shown that genistein has antineoplastic effects against ovarian cancer. Several epidemiological studies have shown 
that women who have high consumption of isoflavones have a relatively low incidence of ovarian cancer. Genistein 
inhibits ovarian carcinogenesis by pleiotropic mechanisms. A higher affinity to estrogen receptor β is one probable 
explanation for its ability to reduce the risk of ovarian cancer. Genistein also targets multiple cellular signal transduction 
pathways associated with cell cycle regulation and apoptosis. In addition, genistein has been suggested to have 
antiangiogenic and antioxidant activities. Herein, we summarize recent results from epidemiological and experimental 
studies to identify the role of genistein in ovarian cancer. Further studies are needed to achieve conclusive results and 
determine the clinical applications of genistein.
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Introduction
Previous epidemiological studies have reported that 
soy products play an important role in reducing the 
incidence and mortality rates of breast and prostate 
cancers (Kasiske et al., 1991; Lee et al., 1991; Lee et al., 
2003; Magee and Rowland, 2004; Peeters et al., 2003). 
Soybeans and most soy products contain large amounts 
of isoflavones called soy phytoestrogens, which mainly 
consist of genistein (60%) and daidzein (30%) with 
smaller quantities of glycitein (10%). Phytoestrogens 
function as natural selective estrogen receptor (ER) 
modulators, depending on the tissue and the presence 
of coregulator proteins (Pike et al., 1999). Because of 
their potential estrogen-antagonistic effects, they have 
been reported to reduce the risk of hormone-dependent 
tumors (Myung et al., 2009).
Among the components of isoflavones, genistein 
has been extensively investigated to determine its 
chemopreventive and therapeutic activities. Several 
in vitro and in vivo studies have shown that genistein 
inhibits the carcinogenesis of non-hormone-dependent 
tumors such as colon, gastric, lung, and pancreatic 
tumors (Andres et  al . ,  2011).  Genistein exerts 
pleiotropic effects through the modulation of genes 
related to the cell cycle and apoptosis (Banerjee et al., 
2008). In addition, genistein has been suggested to 
inhibit angiogenesis and antioxidant events through its 
molecular targets.
Among gynecologic malignancies, ovarian and 
endometrial cancers are related to hormonal and 
This is an open access article under the CC BY-NC-ND license.
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reproductive events. Like breast and prostate cancers, 
ovarian cancer occurs less frequently in Asian countries, 
where a high-soy diet is consumed, than in Western 
countries (Adlercreutz et al., 1993; Parkin et al., 
1999). Furthermore, numerous studies have shown 
that genistein has protective effects against ovarian 
carcinogenesis (Andres et al., 2011; Kim et al., 2011). 
Herein, we summarize the available evidence on the 
chemopreventive and therapeutic potentials of genistein 
in ovarian cancer as follows: first, we discuss the 
anticancer mechanisms of genistein in ovarian cancer; 
second, we review epidemiological studies that aimed to 
determine the relation between soy intake and ovarian 
cancer risk; third, we review in vitro and in vivo studies 
that demonstrate the anticancer effects of genistein.
Anticancer Mechanisms of Genistein in 
Ovarian Cancer
Ovarian Carcinogenesis
Although the etiology of ovarian cancer is not 
completely understood, 2 dominant hypotheses 
regarding the underlying mechanisms of ovarian 
carcinogenesis have long been suggested. One is the 
ovulation hypothesis, which states that ovulation 
causes trauma to the ovarian epithelium, leading to 
rapid cell proliferation to repair the wound (Fathalla, 
1971). Epidemiological studies have shown that oral 
contraceptive use or pregnancies can reduce ovarian 
cancer risk, thereby supporting this hypothesis. Another 
hypothesis concerns gonadotropin stimulation of the 
ovarian epithelium (Stadel, 1975), which suggests that 
excess stimulation by hormonal factors could result 
in abnormal proliferation or malignant transformation 
of cells.  However,  neither incessant ovulation 
nor gonadotropin stimulation of ovarian estrogen 
gives a completely satisfactory explanation for the 
pathophysiology of ovarian carcinogenesis. 
Recent epidemiological evidence has given rise to a 
growing interest in the role of inflammation in ovarian 
cancer (Ness and Cottreau, 1999). Inflammation with 
rapid DNA damage and repair, oxidative stress, and 
increased levels of biological substances has shown to 
induce carcinogenesis (Ames et al., 1995; Dreher and 
Junod, 1996). Moreover, the ovulation process itself has 
been suggested to be associated with inflammation at 
the level of the epithelium as well as the follicle (Kim 
et al., 2011). Additional risk factors for ovarian cancer, 
including asbestos and talc exposure, endometriosis, 
and pelvic inflammatory disease, can cause local 
inflammation but do not directly affect ovulation and 
hormone levels. Epidemiological studies have shown 
that these factors, which can cause local inflammation, 
can increase ovarian cancer risk (Ness and Cottreau, 
1999).
Pleiotropic Actions of Genistein in Ovarian 
Cancer
Genistein has been shown to inhibit  ovarian 
carcinogenesis and cancer cell growth through its 
pleiotropic mechanisms against ER, cell proliferation, 
apoptosis, angiogenesis, metastasis, and oxidation 
(Figure 1). The hormonal actions of genistein are 
suggested to exert anticancer effects (Andres et al., 
2011; Myung et al., 2009). Genistein has a high affinity 
for binding to ER, particularly ER-β, which is involved 
in the suppression of ER-α-stimulated estrogenic signal 
mechanisms. In addition to having hormonal activity, 
genistein exerts antineoplastic effects by modulating 
multiple signaling pathways such as protein-tyrosine 
kinase (PTK), Akt , NF-κB, matrix metalloproteinases 
(MMPs), and Bax/Bcl-2 (Banerjee et al., 2008; Sarkar 
and Li, 2002). Genistein has an inhibitory effect toward 
PTK, which drives signal transduction pathways 
leading to tumor growth and progression to malignancy 
(Akiyama et al., 1987). Genistein has also been 
demonstrated to inhibit the NF-κB and Akt signaling 
pathways, which play important roles in maintaining the 
homeostatic balance between cell survival and apoptosis 
(Li and Sarkar, 2002). It has also been found that 
genistein exerts antioxidant effects on reactive oxygen 
species by scavenging free radicals (Ruiz-Larrea et al., 
Figure 1. Pleiotropic effects of genistein on the inhibition of ovarian 
carcinogenesis. The high affinity of genistein to estrogen receptor β 
has an anticancer effect on ovarian cancer cells. In addition, genistein 
modulates multiple cellular signal transduction pathways associated 
with cell proliferation, apoptosis, angiogenesis, metastasis, oxidative 
stress, and autophagic cell death.
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1997). Moreover, genistein can inhibit angiogenesis and 
metastasis (Li et al., 1999). 
Anticancer Effects of Genistein on 
Ovarian Cancer 
Epidemiological Evidence
Despite the extensive literature evaluating the effect 
of phytoestrogens on breast cancer risk, little attention 
has been given to the role of phytoestrogens in ovarian 
cancer. Because large variations exist in isoflavone 
consumption between Asian population and Western 
population (who have a low overall consumption), 
the Asian population is considered an ideal setting for 
evaluating the role of isoflavones for preventing the risk 
of cancer (Taylor et al., 2009). In a case-control study 
in China, consumption of a high-soy diet was shown 
to have a significant inverse association with ovarian 
cancer risk. A decreased risk for ovarian cancer was 
found in women with the highest quartile intake of 
genistein than in women with the lowest quartile intake 
(odds ratio [OR], 0.50; 95% confidence interval [CI], 
0.30–0.84) (Zhang et al., 2004). In Japan, a prospective 
cohort study was performed to determine the role of 
soybean curd containing high levels of phytoestrogen 
for preventing cancer risk. In this study, dietary habit 
had no effect on ovarian cancer risk after adjusting for 
other clinicopathological variables (Sakauchi et al., 
2007).
A recent meta-analysis showed that the highest soy 
intake was associated with a lower ovarian cancer 
risk than the lowest soy intake (OR, 0.61; 95% CI, 
0.42–0.66) (Myung et al., 2009). Due to the growing 
interest in the role of high-soy diets, several studies in 
Western countries have been performed to determine 
the effects of phytoestrogens on ovarian cancer risk. 
Considering the association between a high-soy diet 
and breast cancer risk, it is interesting that a slightly 
stronger effect was observed among Western women 
than among Asian women (Trock et al., 2006). This may 
suggest that intervention with a phytoestrogen over a 
short period can be effective, and prior consumption 
over a number of years is not required (Taylor et al., 
2009). In Italy, the highest quintile intake of isoflavones 
significantly reduced the development of ovarian 
cancer when compared with the lowest quintile intake 
(OR, 0.51; 95% CI, 0.37–0.69) (Rossi et al., 2008). 
A statistically significant inverse association was 
found between genistein and ovarian cancer risk in the 
California Teachers Study cohort (P for trend = 0.07). 
A 46% reduction in ovarian cancer risk was observed 
in women who consumed >3 mg/day of isoflavones 
as compared to women who consumed <1 mg/day of 
isoflavones (OR, 0.56; 95% CI, 0.33–0.96) (Chang 
et al., 2007). Moreover, an inverse association was 
suggested between total phytoestrogen consumption and 
ovarian cancer risk. The highest tertile intake of total 
phytoestrogen was significantly associated with a lower 
risk of ovarian cancer than the lowest tertile intake, 
after adjusting for other variables (OR, 0.62; 95% CI, 
0.38–1.00) (Bandera et al., 2011). In contrast, 3 studies 
in Western countries showed no significant association 
between phytoestrogen intake and ovarian cancer risk 
in Swedish women. These conflicting results might be 
due to the differences in dietary habits. For example, 
in the Italian study, the largest dietary contributors to 
isoflavone intake were soy and soymilk; however, in 
the Swedish study, the largest dietary contributors to 
isoflavone intake were beans or vegetables (Hedelin et 
al., 2011). Out of the 6 studies reviewed by us, we found 
that 4 studies showed a trend for inverse association 
(Table 1). There were considerable variations in the 
amount of soy consumed and confounding variables 
between each study. Additional cohort studies and 
randomized controlled trials are needed to confirm the 
role of genistein in ovarian cancer development. 
In vitro Studies
Results from previous epidemiological studies have 
raised the interest regarding the role of genistein as a 
chemopreventive agent, and therefore, researchers have 
attempted to determine the molecular mechanisms of 
this compound. Numerous studies have shown that 
genistein has inhibitory effects on ovarian cancer cells 
and tumor growth in vitro. Table 2 shows the anticancer 
effects of genistein on ovarian cancer cells from recently 
published in vitro studies.
Hormonal Effects
ER has 2 different forms—α and β—that vary with 
respect to tissue-specific expression and transcriptional 
activities (Mosselman et al., 1996). The structure of 
genistein is closely similar that of 17β-estradiol, because 
of which genistein binds and activates both ER-α and 
ER-β. ER-α has been mainly found in the endometrium, 
breast, ovarian stroma, and hypothalamic tissue, whereas 
ER-β has been mainly documented in the kidney, brain, 
bone, heart, lungs, intestinal mucosa, prostate, and 
endothelial cells (Couse et al., 1997). ER-α activation 
is related to cell proliferation and carcinogenesis in 
estrogen-dependent tumors (Oesterreich et al., 2001). 
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Table 1. Effects of genistein on ovarian cancer development from different epidemiological studies
Reference Study design Study period Participants Race/Country Measure of soy intake
Adjusted OR  
(95% CI)
Zhang et 
al.,2004
CCS 1999–2000 254 EOC cases and
652 age-matched 
controls
Chinese/China Soy foods (g/day): ≥136.4 vs. ≤47.0
Isoflavones (mg/day): ≥32.8 vs. ≤11.6
Genistein (mg/day): ≥20.9 vs. ≤6.6
0.50 (0.31–0.82)
0.51 (0.31–0.85)
0.50 (0.30–0.84)
Sakauchi et al., 
2007
PCS 1988–
2003(15)
77 EOC cases among 
63,541 women
Japanese/Japan Soybean curd (times/week)
Almost every day vs. ≤1–2 
0.61 
 (0.26–1.45)
Rossi et al.,
2008
CCS 1992–1997 1031 EOC cases and  
2411 controls
Italian/Italy Isoflavone (μg/day)  
≥32.5 vs. ≤12.8
0.51  
(0.37–0.69)
Chang et al.,
2007
PCS 1995–
2003(8)
280 EOC cases 
among 97,275 
women
Mainly white (84%), 
Hispanic (4%),Asian 
(3%), black (2%), Native 
American (2%)/U.S.
Isoflavone (mg/day) ≥3 vs. ≤1
Genistein (mg/day) ≥1.1 vs. ≤0.3
0.56 (0.33–0.96)
0.65 (0.42–1.02)
Bandera et al., 
2011
CCS 2004–2008 205 EOC cases and  
390 controls
White (87%), black(4%),  
Hispanic (4%)/U.S.
Total phytoestrogen (mg/1000 kcal) 
≥1395 vs. ≤534
0.62  
(0.38–1.00)
Hedelin et al., 
2011
PCS 1991–
2007(16)
163 EOC cases
(117 invasive cancer, 
6 BT)
among 47,140 
women
Swedish/Sweden Isoflavone (μg/day)  
≥16 vs. ≤0.74
1.26  
(0.79–2.01)
CCS: case-control study, PCS: prospective cohort study, EOC: epithelial ovarian cancer, BT: borderline tumor
Table 2. Effects of genistein on ovarian cancer cell lines from in vitro studies
Reference Materials Cell type Description Measure of interest Results
Choi et al.,
2007
Genistein SK-OV-3 Human 
ovarian cancer 
cell
Cell proliferation (MTT assay)
Cell cycle distribution (FACS)
Cytotoxicity (LDH)
Apoptosis (caspase-3 activity)
Inhibition of cell proliferation in a dose- and 
time-dependent manner
Arrest at G2/M phase
Increased LDH release
Increased caspase-3 activity 
Ahmed et 
al., 
2011
ITB-301, 
genistein 
derivative
SK-OV-3, ES2,
HeyA8, 
HeyA8-MDR
Human 
ovarian cancer 
cell
Cell proliferation (crystal violet staining)
Cell cycle distribution (FACS)
Apoptosis (caspase-3/7 activity)
Microtubule depolymerization (tubulin 
polymerization assay kit)
Induced microtubule depolymerization in a 
dose- and time-dependent manner
No change in efflux-mediated drug resistance 
Cytotoxic effect of ITB-301 on a multidrug-
resistant cell line
Solomon et 
al., 2008
Genistein A2780, C200 Human 
ovarian cancer 
cell
Cell survival and apoptosis 
(MTT assay, histone-DNA ELISA)
Indirect measure of apoptosis: 
Bcl-2, Bcl-xL, c-IAP1, survivin 
(Western blot analysis)
NF-κB (EMSA)
Downregulation of antiapoptotic genes
Decreased NF-κB
Genistein pretreatment with chemotherapy 
was effective 
in both PS and PR ovarian cancer cell lines
Gercel-
Taylor 
et al., 2004
Genistein 5 ovarian 
cancer cell lines
from stage IIIc
Human 
ovarian cancer 
cell
Cell growth 
(sulforhodamine B and colony formation 
assays)
Apoptosis (caspase-3 activity)
Induced caspase-3 activity 
Additive effect of cell proliferation inhibition 
with cisplatin, topotecan, and paclitaxel
Luo et al., 
2008
Genistein OVCAR-3 Human 
ovarian cancer 
cell
Cytotoxicity (CytoTox 96)
Proliferation (CellTiter 96)
VEGF (RT-PCR, ELISA)
Induced cell growth
Inhibited VEGF expression
Rucinska et 
al., 2007
G8CG CHO Chinese 
hamster ovary 
cell
Cytotoxicity (MTT assay)
DNA damage (Comet assay)
Apoptosis 
(Hoechst 33258/propidium iodide staining 
technique)
ROS (fluorescence probe)
Cytotoxic at high concentrations
Antioxidant properties at lower 
concentrations
Chen et al., 
2001
Genistein Caov-3, NIH:
OVCAR-3
Human 
ovarian cancer 
cell
Cell proliferation (MTT assay)
ER, GAPDH (RT-PCR)
IL-6 (ELISA)
TGF-b (immunoassay)
Inhibited cell proliferation
Inhibited IL-6 synthesis 
Increased TGF-b production 
Gossner et 
al., 2007
Genistein A2780, CaOV3, 
ES2
Human 
ovarian cancer 
cell
Analysis of apoptosis (FACS)
Autophagy (microtubule-associated LC3)
Akt (western blot analysis), glucose uptake
Induced apoptosis
Inhibited glucose uptake, reduced 
phosphorylated Akt
Induced autophagic cell death
MTT: methyl thiazolyl tetrazolium, FACS: fluorescence-activated cell sorting, LDH: lactate dehydrogenase, ELISA: enzyme-linked immunosorbent 
assay, EMSA: electrophoretic mobility shift assay, PS: platinum sensitive, PR: platinum resistant, VEGF: vascular endothelial growth factor, RT-PCR: 
reverse transcription polymerase chain reaction, G8CG: genistein 8-C-glucoside, ROS: reactive oxygen species, ER: estrogen receptor, GADPH: 
glyceraldehyde-3-phosphate dehydrogenase, LC3: light chain 3
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ER-β has been suggested to play a role in suppressing 
ER-α-mediated cell proliferation (Strom et al., 2004). 
Furthermore, overexpression of ER-β in cancer cells 
has been shown to have antitumoral effects (Treeck 
et al., 2007). Normal ovary contains equal amounts 
of ER-α and ER-β mRNAs (Brandenberger et al., 
1998). However, 90% of ovarian cancers arise from 
the epithelial layer, which predominantly expresses 
ER-α, whereas ER-β is expressed predominantly in 
the granulosa cells (Chu et al., 2000). Previous studies 
have suggested that ER-α might be associated with 
the development of reproductive neoplasms. Thus, 
activation of ER-β could be a promising target to reduce 
ER-α-regulated gene transcription. 
The binding affinity of genistein for ER-α is reported 
to be 4% and that for ER-β is 87%, in comparison 
with estradiol (Kuiper et al., 1998). Therefore, it is 
suggested that genistein blocks the binding of more 
potent estrogens to receptors, thereby playing a potential 
role in preventing endocrine-related cancers. In addition 
to acting as a competitive ligand to estradiol, genistein 
has a higher affinity for ER-β than ER-α (Harris et 
al., 2005). This higher affinity to ER-β is considered a 
possible mechanism for decreasing ovarian cancer risk 
(Myung et al., 2009). 
Effects Genistein on Cell Cycle Regulation
Genistein has been identified as a growth inhibitor 
of several cancer cells. The inhibition of cancer cell 
growth could be due to cell cycle arrest, which results in 
cessation of cell proliferation. By using ovarian cancer 
cells (SK-OV-3 cells), it was shown that genistein 
causes cell cycle arrest in the G2/M phase in a dose- 
and time-dependent manner. The proportion of cells 
in the G2/M phase after 48 hr exposure increased 
according to genistein concentration (Choi et al., 2007). 
In HO-8910 cells, genistein altered the levels of proteins 
associated with the checkpoint pathway, with a trend of 
inhibition of cancer cells proliferation (Ouyang et al., 
2009). Moreover, the genistein derivative, ITB-301, also 
inhibits cell proliferation and induces cell cycle arrest in 
ovarian cancer cells by microtubule depolymerization. 
Subsequent mitotic arrest by the cytotoxic effect of 
ITB-301 was also observed in drug-resistant cancer 
cell lines, suggesting its therapeutic potential against 
multidrug-resistant cancers (Ahmed et al., 2011).
Effects on Apoptosis
Another antineoplastic action of genistein is 
programmed cell death (apoptosis). Several molecular 
mechanisms on how genistein induces apoptosis have 
been suggested. Some researchers have investigated 
the relation between genistein and the Bcl-2 family 
(Banerjee et al., 2008; Kyle et al., 1997; Spinozzi et al., 
1994). The Bcl-2 family is the most well-known protein 
family that mediates apoptosis; Bcl-2 family proteins 
are classified into 2 main groups according to their 
functional characteristics: antiapoptotic proteins, such 
as Bcl-xL and Bcl-2, and pro-apoptotic proteins, such 
as Bax, Bak, and Bad. Genistein also induces growth 
inhibition and apoptosis by inhibiting the NF-κB and 
Akt signaling pathways (Brunet et al., 1999; Cardone 
et al., 1998; Van Antwerp et al., 1996; Wu et al., 1996). 
NF-κB as a transcription factor is an important regulator 
of genes involved in cell survival and proliferation. 
Overexpression of NF-κB is reported to protect cells 
from apoptosis, whereas inhibition of NF-κB suppresses 
cell growth and induces apoptosis (Sarkar and Li, 2002). 
The Akt  signaling pathway is another transduction 
pathway that plays an important role in controlling 
cell survival and apoptosis. Recent studies have shown 
that Akt  also regulates the NF-κB pathway through the 
phosphorylation and activation of molecules involved in 
the NF-κB pathway (Ozes et al., 1999; Romashkova and 
Makarov, 1999). Therefore, the Akt signaling pathway 
has been considered an ideal target for apoptosis 
induction.
Flow cytometry and measurement of caspase-3 
activity are usually performed to detect apoptosis. In a 
previous study, flow cytometry showed that genistein 
induced caspase-3 activity and increased the apoptotic 
population in ovarian cancer cells (SK-OV-3 cells) 
(Choi et al., 2007). Analyses of apoptotic response after 
genistein administration to ovarian cancer cell lines 
showed that 20–25% of cells became apoptotic after 
24–48 hr of treatment (Gossner et al., 2007). Genistein 
has an additive effect of inhibiting cell proliferation 
by inducing caspase-3 activity when used with a 
chemotherapeutic agent (Gercel-Taylor et al., 2004). 
The sensitizing effect of genistein has raised the 
possibility of overcoming the chemoresistance of 
ovarian cancer. In both platinum-sensitive (A2780) and 
platinum-resistant (C200) ovarian cancer cell lines, 
pretreatment with genistein followed by administration 
of a chemotherapeutic agent resulted in the inhibition 
of cell growth by inactivation of NF-κB. Antiapoptotic 
genes such as Bcl-2, Bcl-xL, survivin, and c-IAP, which 
are also the downstream genes of NF-κB, were found to 
be downregulated (Solomon et al., 2008). 
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Effects on Angiogenesis and Metastasis
Genistein has been shown to inhibit the angiogenesis 
and metastasis of cancer cells (Fotsis et al., 1995). In 
breast cancer cells, administration of genistein inhibited 
MMPs, the proteolytic enzymes involved in cancer 
invasion (Li and Sarkar, 1999). Angiogenesis of solid 
tumors is involved in promoting the proliferation, 
invasion, and metastasis of cancer cells. Therefore, 
recent studies have focused on antiangiogenesis for 
cancer therapy and prevention (Carmeliet and Jain, 
2000). Vascular endothelial growth factor (VEGF) is one 
of the most promising targets for ovarian cancer therapy. 
VEGF and VEGF receptors are expressed in ovarian 
cancer cells and are associated with angiogenesis 
and metastasis. Several VEGF-targeting agents have 
shown to be beneficial in patients with advanced-
stage malignancies as well as in adjuvant settings. The 
effects of flavonoids, including genistein, on ovarian 
cancer cells (OVCAR-3) have been investigated (Luo 
et al., 2008). Five of the 12 studied flavonoids not only 
inhibited cell proliferation but also inhibited VEGF 
expression. Among the various isoflavones, genistein 
has the highest potency of inhibiting VEGF protein 
secretion; interestingly, it is even more potent than 
cisplatin.
Antioxidant Effects
Several flavonoids are known to function as 
antioxidants and scavengers of free oxygen radicals 
(Ruiz-Larrea et al., 1997). The protective effect of 
genistein against oxidative stress-induced injury 
depends on the modulation of transcription factors. The 
activation of the transcription factors Nrf1 and Nrf2, 
which regulate genes involved in oxidative stress, was 
evaluated (Hernandez-Montes et al., 2006). In addition, 
genistein has been reported to inhibit the generation of 
reactive oxygen species, which are known to increase 
under conditions of oxidative stress, by modulating NF-
κB (Davis et al., 2001). In ovarian cancer, genistein 
can affect cancer cells differently according to its 
concentration. Although genistein-8-C-glucoside at 
high concentrations (10–130 μM) significantly reduced 
cell viability by inducing apoptosis and DNA damage, 
genistein at low concentrations (5–7.5 μM) showed 
antioxidant properties without cytotoxic or genotoxic 
effect (Rucinska et al., 2007).
Other Effects 
The proliferation of ovarian cancer cells is inhibited 
by regulating cytokine synthesis. Genistein has been 
shown to inhibit the proliferation of ovarian cancer cells 
by modulating the cytokine IL-6, which affects immune 
homeostasis and inflammatory reactions (Chen and 
Anderson, 2001).
Autophagy, a lysosomal degradation pathway, is 
a cellular response to environmental stresses such as 
nutrient starvation. A study investigating the mechanism 
of genistein-induced cell death in ovarian cancer showed 
that genistein treatment results in caspase-independent 
and autophagic cell death (Gossner et al., 2007). 
Although normal cells utilize oxidative phosphorylation 
in the presence of oxygen to generate energy, cancer 
cells depend on glycolysis to supply their metabolic 
requirements. This accelerated rate of glycolysis in the 
presence of oxygen is known as the “Warburg effect” 
(Semenza et al., 2001; Weber, 1977). The oncogene Akt 
has been reported to induce accelerated glycolysis in 
cancer cells (Elstrom et al., 2004). Genistein may inhibit 
glucose uptake by inhibiting Akt activation, and thereby 
induce autophagic cell death. 
In vivo Studies
Although epidemiological and in vitro  studies 
have shown the protective effects of genistein against 
ovarian cancer, concerns regarding the safety of 
isoflavones have been raised because of undetermined 
results from in vivo studies. It has been shown that the 
hormonal activities of genistein may promote increased 
risks of endocrine-dependent tumors such as breast, 
endometrial, and ovarian cancers (Allred et al., 2001; 
Seo et al., 2006). Undesirable results in uterine cancer 
have also been reported. In ovariectomized rats, uterine 
weight increased after a high oral genistein dose (54 
mg·kg b.w.-1·day-1 for 3 months) (Rimoldi et al., 2007). 
Meanwhile, genistein (10 mg·kg b.w.-1·day s.c.-1 for 
3 days) showed an antagonistic effect on estradiol-
induced increase in uterine epithelial height (Diel et 
al., 2006). Moreover, genistein (1 mg·30 g b.w.-1·every 
4 weeks s.c.-1 for 30 weeks) showed a protective effect 
against the development of endometrial cancer and 
atypical endometrial hyperplasia in mice by modulating 
the expression of estrogen-related genes and cytokines 
(Lian et al., 2001).
For the ovaries, similar results as those for the 
uterus were observed in female piglets that received 
isoflavones through a high-soy diet (2.8 mg·kg 
b.w.-1·day-1 for 6 weeks). These piglets developed 
heavier ovaries with more follicles (De Wilde et al., 
2007). Genetically susceptible female mice reared on 
an isoflavone-supplemented diet (125 μg/g each of 
genistein and daidzein for 8 weeks) developed a higher 
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granulosa cell tumor frequency (22%) than mice reared 
on an isoflavone-free diet (11%) (Dorward et al., 2007). 
However, dietary administration of genistein resulted 
in a significant reduction in dimethylbenz[a]anthracene 
(DMBA)-induced ovarian cancer in female Sprague-
Dawley rats. DMBA-treated female rats received a 
supplementary diet containing 250 ppm of genistein 
for 50 weeks and showed 100% reduction in cancer 
development (Tanaka et al., 2002). 
Conclusion
Collect ively,  previous  epidemiological  and 
experimental studies have suggested that genistein 
may play promising roles as a chemopreventive or 
therapeutic agent against ovarian cancer. In addition to 
its hormonal action, the anticancer effects of genistein 
are related to multiple cellular signaling pathways such 
as PTK, Akt , NF-κB, MMP, and Bax/Bcl-2. Because 
the successful treatment of ovarian cancer is limited 
mainly by the development of chemotherapy resistance, 
genistein is expected to play a role in sensitizing 
multiresistant ovarian cancer cells and have additive 
effects with conventional chemotherapeutic agents. 
Although some clinical trials are now being performed 
to identify the role of genistein as an anticancer agent 
against various types of cancers, there is currently 
no registered clinical trial on ovarian cancer. Further 
research should be performed to identify the role of 
genistein in ovarian carcinogenesis.
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